Curium refiles for Lantheus Holdings, Inc. (LNTH) acquisition
Curium’s September 21 antitrust refiling starts a new waiting period for its acquisition of Lantheus.
Lantheus Holdings, Inc. (LNTH) said Curium US Holdings LLC resubmitted its U.S. antitrust notification on September 21, 2026, starting a new 30-day waiting period for its acquisition of Lantheus. Curium voluntarily withdrew the notification on September 17 to give the Federal Trade Commission additional review time.
Curium develops, manufactures and supplies radioactive medicines for diagnosis and treatment, and Lantheus provides diagnostic imaging products used in areas including prostate cancer imaging and cardiac ultrasound. Under the agreement announced August 3, Curium US would acquire all outstanding Lantheus shares through a merger, making Lantheus its wholly owned subsidiary.
Lantheus shareholders would receive $102.50 per share in cash at closing, plus non-transferable contingent value rights offering up to $12 per share in additional cash payments if specified commercial milestones are achieved through 2030.
The new waiting period is scheduled to expire on October 21, 2026, unless terminated earlier or extended, including through an FTC request for additional information and documents. Completion remains subject to required regulatory approvals, Lantheus shareholder approval and other closing conditions.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Curium to Buy Lantheus in $8 Billion Cash-and-CVR Deal